Stryker Corporation $SYK Shares Purchased by Intech Investment Management LLC

Intech Investment Management LLC boosted its position in shares of Stryker Corporation (NYSE:SYK) by 36.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,011 shares of the medical technology company’s stock after acquiring an additional 3,227 shares during the quarter. Intech Investment Management LLC’s holdings in Stryker were worth $4,222,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Czech National Bank grew its holdings in Stryker by 3.9% during the 4th quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after acquiring an additional 3,366 shares in the last quarter. Davis R M Inc. raised its holdings in shares of Stryker by 1.8% in the 3rd quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock valued at $51,285,000 after purchasing an additional 2,512 shares in the last quarter. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Stryker during the 3rd quarter worth $27,952,000. Daymark Wealth Partners LLC lifted its position in shares of Stryker by 436.0% during the 4th quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after purchasing an additional 37,307 shares during the last quarter. Finally, Wealthcare Advisory Partners LLC grew its stake in shares of Stryker by 265.2% during the fourth quarter. Wealthcare Advisory Partners LLC now owns 9,328 shares of the medical technology company’s stock worth $3,278,000 after purchasing an additional 6,774 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.45, for a total transaction of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares in the company, valued at $50,170.65. This represents a 95.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 323,264 shares of company stock valued at $100,659,489 in the last ninety days. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

Shares of NYSE SYK opened at $299.15 on Tuesday. The stock has a market cap of $114.68 billion, a P/E ratio of 34.62, a P/E/G ratio of 1.92 and a beta of 0.80. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The stock has a 50 day moving average of $321.00 and a two-hundred day moving average of $347.64. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.84 earnings per share. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s payout ratio is 40.74%.

Wall Street Analysts Forecast Growth

SYK has been the topic of a number of analyst reports. Canaccord Genuity Group cut their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Citigroup dropped their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Wells Fargo & Company cut their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $465.00 price target on shares of Stryker in a report on Wednesday, March 4th. Finally, Robert W. Baird set a $385.00 price target on shares of Stryker in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.